Abstract:Previously we have shown that tyrosine 718 of ASK1 when phosphorylated is critical for SOCS1 binding and SOCS1-mediated degradation of ASK1. However, the kinase and phosphatase responsible for phosphorylation and dephosphorylation of ASK1 at Tyr-718 are unknown. In this study, we identified JAK2 and SHP2 as a Tyr-718-specific kinase and phosphatase, respectively. Interferon-gamma (IFN-gamma) induced degradation of ASK1 in normal but not in SOCS1-KO endothelial cells (EC). IFN-gamma-induced tyrosine phosphorylation of ASK1 at Tyr-718 was blocked by a JAK2-specific inhibitor. IFN-gamma enhanced the association between JAK2 and ASK1, and the ASK1-JAK2 complex was labile and was stabilized by the proteasomal inhibitor MG132. Furthermore, JAK2, but not JAK1, directly bound to and phosphorylated ASK1 at Tyr-718, leading to an enhanced association of ASK1 with SOCS1 and subsequent ASK1 degradation. Next, we showed that overexpression of the SH2-containing protein-tyrosine phosphatase-2 (SHP2) augmented, whereas a phosphatase-inactive mutant of SHP2 inhibited, TNF-induced ASK1 dephosphorylation. SHP2 associated with ASK1 in response to tumor necrosis factor in EC. An SHP-2 substrate-trapping mutant formed a complex with tyrosine-phosphorylated ASK1, suggesting that ASK1 is a direct SHP2 substrate. Moreover, SHP2 wild type, but not a catalytically inactive mutant, dissociated SOCS1 from ASK1. IFN-gamma-induced ASK1 Tyr(P)-718 was enhanced in mouse EC deficient in SHP2 (SHP2-KO). In contrast, tumor necrosis factor-induced dephosphorylation of ASK1 at Tyr(P)-718 and activation of ASK1-JNK signaling, as well as EC apoptosis, are significantly reduced in SHP2-KO EC. Our data suggest that JAK2-SOCS1 and SHP2 reciprocally regulate ASK1 phosphorylation and stability in response to cytokines.

Association and Contribution of Erk to Il-6-Induced Activation of Signal Transducer and Activator of Transcription in A Human Myeloma Cell Line

[Study of IL-6 Signal Transduction Pathway in a Human Multiple Myeloma Cell Line--sko-007].

Inhibition of IL-6-induced STAT3 Activation in Myeloma Cells by Protein Kinase A

Function of tyrosine kinase JAK1 in IL-6-induced activation of JAK/STAT signal transduction pathway

Involvement of STAT3/APRF in IL-6 signal transduction pathway

Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNalpha.

Figure S2 from JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNα

Expression and Functions of the STAT3-SCLIP Pathway in Chronic Myeloid Leukemia Cells.

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

JAK2 and SHP2 Reciprocally Regulate Tyrosine Phosphorylation and Stability of Proapoptotic Protein ASK1.

[Activation of PKA Pathway Inhibits Reactivity of Human Myeloma Cell Line-U266 to IL-6].

Antagonistic effect between two IL-6 signal transduction pathways in a human myeloma cell line-U266

The biological function of IL-6 on a human multiple myeloma cell-KM-3 is mediated by Ras/NF-IL-6 signal transduction pathway

Stat3 Exerts Two-Way Regulation In The Biological Effects Of Il-6 In M1 Leukemia Cells

IL-6 Inhibits Apoptosis of Human Myeloma Cell Line XG-7 Through Activation of JAK/STAT Pathway and Up-Regulation of Mcl-1.

Comparison of IL-6-induced STAT1 Activation in Different Responsive Cells.

Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK)

Camp Inhibits the Proliferation and IL-6 Signal Transduction of Multiple Myeloma Cell

Behavioral variability within the Brattleboro and Long-Evans rat strains

ERK is a negative feedback regulator for IFN-γ/STAT1 signaling by promoting STAT1 ubiquitination